{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3115, 
        3124
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3216, 
        3225
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3321, 
        3335
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2887, 
        2910
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5137, 
        5157
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2940, 
        2967
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3035, 
        3040
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5031, 
        5036
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5072, 
        5076
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5037, 
        5054
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5077, 
        5094
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        599, 
        628
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4888, 
        4923
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4965, 
        4991
      ]
    }
  ], 
  "Negative Findings Phraseology (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3091, 
        3124
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3192, 
        3225
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3004, 
        3010
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3104, 
        3114
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3205, 
        3215
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3337, 
        3350
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3351, 
        3356
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3311, 
        3320
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5112, 
        5120
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2969, 
        2970
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3032, 
        3033
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3132, 
        3133
      ]
    }, 
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4", 
      "__extent": [
        3233, 
        3235
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4993, 
        4994
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5028, 
        5029
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5069, 
        5070
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5109, 
        5110
      ]
    }
  ], 
  "Synoptic Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3489, 
        3506
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D0934312^CLIA|eMARCPlus|TN Cancer Registry|20170919125859||ORU^R01^ORU_R01|201709191258590001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-UR-003937^PathSys^44D0934312^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170807000000|||||||20170807000000|&Soft Tissue, other than tumor,mass,lipoma,debride, Lymph Node, Biopsy, Lymph Node, Biopsy, Prostate, Radical Resection, PQRS Radical Prostatectomy|1851352009^^^^^^MD^^CMS^D^^^NPI||||||20170808000000|||F||||||C61^Malignant neoplasm of prostate^I10|1689993529&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\n1. Received in fixative labeled \"\" and \"preprostatic fat\" is a 5.0 x 2.3 x 1.5 cm piece of soft, yellow-tan, focally erythematous adipose tissue. Serial sectioning of the specimen reveals no definite lymph nodes or discrete lesions. Representative sections are submitted in cassette 1A. 3/1. 2. Received in fixative labeled \"\" and \"right pelvic lymph node\" is a 4.0 x 2.6 x 1.5 cm piece of yellow lobulated adipose tissue. Serial sectioning of the specimen reveals a 2.5 x 1.2 x 1.0 cm pink-gray, partially fatty lymph node. The node is serially sectioned and totally submitted in cassette 2A. 6/1. 3. Received in fixative labeled \"\" and \"left pelvic lymph node\" is a 4.0 x 2.0 x 1.4 cm piece of yellow lobulated adipose tissue. Serial sectioning of the specimen reveals 2 pink-tan lymph nodes (1.4 x 0.7 x 0.6 cm and 2.2 x 1.5 x 0.9 cm). The smaller node is serially sectioned and totally submitted in cassette 3A, 4/1. The larger node is serially sectioned and totally submitted in cassette 3B, 5/1. 4. Received in fixative labeled \"\" and \"prostate\" is a 146 g specimen consisting of a prostate gland (7.5 x 5.9 x 5.3 cm) with attached bilateral seminal vesicles (2.6 and 2.2 cm in length), and attached bilateral vasa deferentia (3.5 and 4.1 cm in length). The external surface of the prostate is pink-tan to brown and granular with a small amount of attached adipose tissue and focal cautery artifact. The right side of the specimen is marked with red ink and the left side is marked with blue ink. Serial sectioning of the prostate reveals a glistening gray-tan, finely nodular cut surface. The nodules (0.4 to 2.7 cm in maximum dimension) extend from the left and right apex to the left and right base. There are numerous hemorrhagic cysts (0.1 to 0.3 cm in maximum dimension) identified within the posterior aspect of the prostate. There are focal black calculi identified within the cyst. No discrete masses are noted within the prostate. Representative sections are submitted as follows: 4A, apical margin, 5/1; 4B, bladder neck margin, 5/1; 4C, right seminal vesicle and vas deferens, 2/1; 4D, left seminal vesicle and vas deferens, 2/1; 4E-4M, right prostate from apex to base, 1/1 each; 4N-4V, left prostate from apex to base, 1/1 each. (AC2)\n\n\nPath report.relevant Hx\n\nHistory - Prostate cancer\n\n\nPath report.final diagnosis\n\n1. Preprostatic fat, excision:     Benign fibroadipose tissue. 2. Right pelvic lymph node, dissection:     One lymph node negative for metastatic carcinoma (0/1). 3. Left pelvic lymph nodes, dissection:     Two lymph nodes negative for metastatic carcinoma (0/2). 4. Prostate, seminal vesicles and vasa deferentia, radical prostatectomy:     Prostatic adenocarcinoma, Gleason score 4+3=7 (Grade Group 3).     The tumor is organ confined.     The seminal vesicles, vasa deferentia and all margins are negative for tumor. CANCER CHECKLIST: PROSTATE GLAND: Radical Prostatectomy 3.000.001.1000043 SPECIMEN  Procedure: Radical prostatectomy Prostate Size  Prostate Weight (g): 146grams  Prostate Size in Centimeters (cm): 7.5 x 5.9 x 5.3cm TUMOR  Histologic Type: Acinar adenocarcinoma Histologic Grade  Gleason Pattern: Gleason pattern  Percentage of Pattern 4: 70%  Primary Gleason Pattern: Pattern 4  Secondary Gleason Pattern: Pattern 3  Tertiary Gleason Pattern#: Not applicable  Total Gleason Score: 7  Grade Group: Grade group 3  Intraductal Carcinoma (IDC): Not identified Tumor Extent  Tumor Quantitation: Estimated percentage of prostate involved by tumor (specify %)  Estimated percentage of prostate involved by tumor (specify %): <5%  Extraprostatic Extension (EPE): Not identified  Urinary Bladder Neck Invasion: Not identified  Seminal Vesicle Invasion: Not identified Accessory Findings  Treatment Effect: No known presurgical therapy MARGINS  Margins: Uninvolved by invasive carcinoma LYMPH NODES  Number of Lymph Nodes Involved: None identified  Number of Lymph Nodes Examined: Specify number  Specify number: 3 PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition)  TNM Descriptors: Not applicable  Primary Tumor (pT)#: pT2: Organ confined  Regional Lymph Nodes (pN): pN0: No positive regional nodes  Distant Metastasis (pM)#: Not applicable - pM cannot be determined from the submitted specimen(s)\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\n1. Pre-prostatic fat for permanent 2. Right pelvic lymph node for permanent 3. Left pelvic lymph node for permanent 4. Prostate for permanent\n\n\nPath report.comments\n\nComments - Dominant tumor nodule: Small tumor nodule of Gleason score 4+3=7 (70% pattern 4) involving the left posterior quadrant of the prostate adjacent to the apex. Secondary tumor nodules: Small tumor nodules of Gleason score 3+3=6 involving the prostate bilaterally. Margins: Negative for tumor. Tumor extent: The tumor involves <5% of the overall prostate volume.   The tumor is organ confined.   Seminal vesicles are negative for tumor.   There is no evidence of lymphovascular invasion. Gleason scores can be grouped and range from Grade Group 1 (most favorable) to Grade Group 5 (least favorable). References: Eur Urol. 2015 Jul 9; BJU Int. 2013; 111:753-60.\n\n\n"
}